Skip to main content
TiumBio Co., Ltd. logo

TiumBio Co., Ltd. — Investor Relations & Filings

Ticker · 321550 ISIN · KR7321550006 KO Professional, scientific and technical activities
Open in API
Filings indexed 296 across all filing types
Latest filing 2021-08-17 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 321550

About TiumBio Co., Ltd.

http://www.tiumbio.com/en/

TiumBio is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics for rare and incurable diseases. The company's pipeline targets conditions with high unmet medical needs, including fibrotic diseases, cancer, and rare hematological disorders. Its lead assets include Merigolix (TU2670), an oral GnRH antagonist in clinical development for endometriosis and uterine fibroids, and TU7710, a long-acting recombinant activated factor VII for hemophilia. TiumBio also develops small molecule antagonists targeting the TGF-β signaling pathway for applications in oncology and fibrosis. The company advances its programs through clinical development and strategic global partnerships.

Recent filings

Filing Released Lang Actions
반기보고서 (2021.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-annual Report) for TiumBio Co., Ltd. for the period ending June 30, 2021. It contains detailed financial information, business descriptions, and management disclosures, which aligns with the definition of an Interim/Quarterly Report (IR). It is not an announcement of a report, but the report itself. H1 2021
2021-08-17 Korean
투자판단관련주요경영사항(면역항암제 TU2218 의 미국 FDA 임상 1/2상 시험계획 (IND) 신청)
Legal Proceedings Report Classification · 100% confidence The document is a regulatory filing from a Korean company (TiumBio) regarding a 'Major Management Matter' (투자판단 관련 주요경영사항), specifically the filing of an Investigational New Drug (IND) application with the US FDA for a clinical trial. This type of disclosure is a standard regulatory announcement for material corporate events. Since it does not fit into specific categories like M&A, dividends, or financial reports, and is a formal regulatory disclosure, it falls under the 'Regulatory Filings' category.
2021-07-28 Korean
타법인주식및출자증권취득결정
M&A Activity Classification · 100% confidence The document is a formal regulatory disclosure regarding the acquisition of shares in another company (SK Plasma) by TiumBio. It details the acquisition amount, purpose, and financial status of the target company. This type of disclosure is a standard regulatory filing in South Korea (DART system) concerning corporate investment activities, which falls under the 'Regulatory Filings' category as it does not fit into specific categories like M&A (which usually implies a full takeover or merger) or Capital/Financing (which usually refers to the company's own capital structure).
2021-07-28 Korean
[기재정정]주요사항보고서(유형자산양수결정)
Capital/Financing Update Classification · 95% confidence The document is a regulatory filing from TiumBio regarding the acquisition of tangible assets (real estate). It is explicitly labeled as a 'Correction Report' (정정신고) for a 'Major Report' (주요사항보고서) concerning the decision to acquire tangible assets. This type of disclosure regarding significant corporate transactions, such as asset acquisitions, falls under the category of general regulatory filings as it does not fit into specific categories like M&A (which usually refers to corporate mergers/takeovers) or capital changes. Therefore, it is classified as a Regulatory Filing (RNS).
2021-07-19 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on the Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details the issuance of stock options to employees and executives, including the number of shares, exercise price, and vesting conditions. This type of disclosure regarding capital structure changes and employee compensation via stock options falls under the category of 'Share Issue/Capital Change' (SHA) in the provided taxonomy.
2021-07-16 Korean
주요사항보고서(유형자산양수결정)
Capital/Financing Update Classification · 95% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Financial Services Commission/Korea Exchange regarding the decision to acquire tangible assets (real estate). This type of regulatory filing, which details specific corporate transactions or material events, falls under the 'Regulatory Filings' category as it does not fit into more specific categories like M&A (which usually refers to corporate mergers/takeovers) or capital changes.
2021-07-16 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.